The global tonic-clonic seizures treatment market attained a value of USD 3.2 million in 2021. The market is estimated to grow at a CARG of 6% and is expected to reach a value of USD 5.4 million by 2030. The market growth is expected to be driven by the increased incidences of epilepsy.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
"Grand mal" is an older term for this type of seizure. It combines the characteristic of tonic and clonic seizures, as the name implies. Tonic refers to stiffening, while clonic refers to rhythmical jerking.
The tonic phase occurs first and shows the following signs:
Followed by the tonic, comes the clonic phase which shows the following signs:
Some common causes of seizures in newborns are brain malformations, lack of oxygen during birth, low levels of blood sugar, blood calcium, blood magnesium, bleeding in the brain, and maternal drug use. In children, the common causes are infection and brain tumours. In adults, the causes are congenital conditions, genetic factors, and progressive brain disease. In the geriatric population, the common causes are stroke, Alzheimer’s disease, and head trauma.
For the diagnosis of the tonic-clonic, the medical and history need to be reviewed prior to the following tests, neurological exams, blood tests, electroencephalogram (EEG), Computerized tomography (CT) scan, Magnetic resonance imaging (MRI), Positron emission tomography (PET), and Single-photon emission computerised tomography (SPECT).
According to the global tonic-clonic seizures treatment market research report, the market can be categorised into the following segments:
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Break up by Product Type
Market Break up by Drug Classification
Market Break up by Route of Administration
Market Break up by Therapeutic Channel
Market Break up Region
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Seizures account for 1 to 2% of all emergency visits in the United States. Seizures are reported to affect approximately 11% of people in the United States at some point in their lives. Males experience 1.85 times more acute symptomatic seizures than females, with a lifetime risk of 5.0% in males and 2.7% in females. African Americans are overrepresented in the emergency department compared to white Americans, with an odd ratio of 1:4. Seizures have a bimodal age distribution, occurring in infants as a result of febrile illness and in patients over the age of 75 as a result of structural damage caused by a stroke or trauma.
Because of the increased prevalence of tonic-clonic seizures, the North American region is expected to dominate the market during the forecast period. Cases of Post-Traumatic Epilepsy (PTE) and Post-Traumatic Seizures (PTS) have increased due to increased brain damage from car accidents and other causes.
The continued cooperation of many organisations, institutions, and governments in the fight against stigma associated with epilepsy and seizures has resulted in increased awareness and a corresponding increase in demand for treatment. For example, the World Health Organization (WHO), the International League Against Epilepsy (ILAE), and the International Bureau for Epilepsy (IBE) have launched a global campaign to "bring the disease out of the shadows," increasing public and private efforts to improve care and reduce disease burden. These programmes have raised the profile of epilepsy in many countries, resulting in regional declarations in all six WHO regions.
Increased clinical trial activity has resulted in a stronger product pipeline. Technological advancements and increased investments in R&D activities have paved the way for a variety of novel treatment options. Furthermore, increased healthcare budget and spending and improved healthcare infrastructure are expected to support market growth over the forecast period.
Medication is used by the majority of people to control the seizures.
Many medications for the treatment of tonic-clonic seizures have been approved by the United States Food and Drug Administration (FDA), including: carbamazepine (Carbatrol, Tegretol, Epitol, Equetro) (Carbatrol, Tegretol, Epitol, Equetro), lamotrigine (Lamictal, Lamictal CD, Lamictal ODT, Lamictal XR), (Lamictal, Lamictal CD, Lamictal ODT, Lamictal XR), levetiracetam (Elepsia XR, Keppra, Keppra XR, Spritam) (Elepsia XR, Keppra, Keppra XR, Spritam), lorazepam (Ativan) (Ativan), oxcarbazepine (Trileptal, Oxtellar XR) (Trileptal, Oxtellar XR), phenytoin phenobarbital (Dilantin, Phenytek)
Whereas multiple supplements or alternative treatments are also given to reduces the risk the seizures:
Also, a ketogenic diet, which is high in fat and low in carbohydrates, is also said to aid in the reduction of certain types of seizures in some people.
The report gives an in-depth analysis of the key players involved in the global Tonic-Clonic Seizures Treatment Market, sponsors manufacturing the therapies, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
|Scope of the Report||
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|Breakup by Product Type||
|Breakup by Drug Classification||
|Breakup by Route of Administration||
|Breakup by Therapeutic Channel||
|Breakup by Region||
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
2 Research Methodology
3 Executive Summary
4 Global Tonic-Clonic Seizures Overview
4.1 Guidelines and Stages
4.3 Screening and Diagnosis
4.4 Treatment Pathway
5 Patient Profile
5.1 Patient Profile Model
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Current Scenario Evaluation
6.1 Emerging Therapies and Clinical trials Synopsis
6.2 Patent Landscape
6.2.1 Patent Overview
220.127.116.11 Patent Status and Expiry
18.104.22.168 Timelines from Drug Development to Commercial Launch
22.214.171.124 New Drug Application
126.96.36.199.1 Documentation and Approval Process
6.3 Cost of Treatment
6.4 Regulatory Framework
6.4.1 Regulatory Overview
188.8.131.52 US FDA
184.108.40.206 EU EMA
220.127.116.11 INDIA CDSCO
18.104.22.168 JAPAN PMDA
7 Challenges and Unmet Needs
7.1 Treatment Pathway Challenges
7.2 Compliance and Drop- out Analysis
7.3 Awareness and Prevention Gaps
8 Global Tonic-Clonic Seizures Treatment Market
8.1 Global Tonic-Clonic Seizures Treatment Market Overview
8.2 Global Tonic-Clonic Seizures Treatment Market Analysis
8.2.1 Market Overview
22.214.171.124 Global Historical Tonic-Clonic Seizures Treatment Market Historical Value (2016-2022)
126.96.36.199 Global Forecast Tonic-Clonic Seizures Treatment Market Forecast Value (2023-2031)
8.2.2 Global Tonic-Clonic Seizures Treatment Market by Product Type
188.8.131.52 Market Overview
184.108.40.206.1 Solid Dosage
220.127.116.11.2 Liquid Dosage
8.2.3 Global Tonic-Clonic Seizures Treatment Market by Drug Classification
18.104.22.168 Market Overview
22.214.171.124.6 Aliphatic Carboxylic Acid
8.2.4 Global Tonic-Clonic Seizures Treatment Market by Route of Administration
126.96.36.199 Market Overview
8.3 Global Tonic-Clonic Seizures Treatment Market by Therapeutic Channel
8.3.1 Market Overview
8.4 Global Tonic-Clonic Seizures Treatment Market by Region
8.4.1 Market Overview
188.8.131.52 North America
184.108.40.206 Asia Pacific
220.127.116.11 Latin America
18.104.22.168 Middle East and Africa
9 North America Tonic-Clonic Seizures Treatment Market
9.1 Market Share by Country
9.2 United States of America
9.2.1 Historical Trend (2016-2022)
9.2.2 Forecast Trend (2023-2031)
9.3.1 Historical Trend (2016-2022)
9.3.2 Forecast Trend (2023-2031)
10 Europe Tonic-Clonic Seizures Treatment Market
10.1 Market Share by Country
10.2 United Kingdom
10.2.1 Historical Trend (2016-2022)
10.2.2 Forecast Trend (2023-2031)
10.3.1 Historical Trend (2016-2022)
10.3.2 Forecast Trend (2023-2031)
10.4.1 Historical Trend (2016-2022)
10.4.2 Forecast Trend (2023-2031)
10.5.1 Historical Trend (2016-2022)
10.5.2 Forecast Trend (2023-2031)
11 Asia Pacific Tonic-Clonic Seizures Treatment Market
11.1 Market Share by Country
11.2.1 Historical Trend (2016-2022)
11.2.2 Forecast Trend (2023-2031)
11.3.1 Historical Trend (2016-2022)
11.3.2 Forecast Trend (2023-2031)
11.4.1 Historical Trend (2016-2022)
11.4.2 Forecast Trend (2023-2031)
11.5.1 Historical Trend (2016-2022)
11.5.2 Forecast Trend (2023-2031)
11.6.1 Historical Trend (2016-2022)
11.6.2 Forecast Trend (2023-2031)
12 Latin America Tonic-Clonic Seizures Treatment Market
12.1 Market Share by Country
12.2.1 Historical Trend (2016-2022)
12.2.2 Forecast Trend (2023-2031)
12.3.1 Historical Trend (2016-2022)
12.3.2 Forecast Trend (2023-2031)
12.4.1 Historical Trend (2016-2022)
12.4.2 Forecast Trend (2023-2031)
13 Middle East and Africa Tonic-Clonic Seizures Treatment Market
13.1 Market Share by Country
13.2 Saudi Arabia
13.2.1 Historical Trend (2016-2022)
13.2.2 Forecast Trend (2023-2031)
13.3 United Arab Emirates
13.3.1 Historical Trend (2016-2022)
13.3.2 Forecast Trend (2023-2031)
13.4.1 Historical Trend (2016-2022)
13.4.2 Forecast Trend (2023-2031)
13.5 South Africa
13.5.1 Historical Trend (2016-2022)
13.5.2 Forecast Trend (2023-2031)
14 Global Tonic-Clonic Seizures Treatment Market Dynamics
14.1 Market Drivers and Constraints
14.2 SWOT Analysis
14.3 Porter’s Five Forces Model
14.4 Key Demand Indicators
14.5 Key Price Indicators
14.6 Market Events, Initiatives, and Trends
14.7 Value Chain Analysis
15 Supplier Landscape
15.1 Johnson & Johnson
15.1.1 Company Overview
15.1.2 Product Portfolio
15.1.3 Demographic Reach and Achievements
15.1.4 Mergers and Acquisitions
15.2 GSK plc
15.2.1 Company Overview
15.2.2 Product Portfolio
15.2.3 Demographic Reach and Achievements
15.2.4 Mergers and Acquisitions
15.3 Takeda Pharmaceutical
15.3.1 Company Overview
15.3.2 Product Portfolio
15.3.3 Demographic Reach and Achievements
15.3.4 Mergers and Acquisitions
15.4 Teva Pharmaceutical Industries
15.4.1 Company Overview
15.4.2 Product Portfolio
15.4.3 Demographic Reach and Achievements
15.4.4 Mergers and Acquisitions
15.5 UCB Celltech
15.5.1 Company Overview
15.5.2 Product Portfolio
15.5.3 Demographic Reach and Achievements
15.5.4 Mergers and Acquisitions
15.6 Abbott Laboratories
15.6.1 Company Overview
15.6.2 Product Portfolio
15.6.3 Demographic Reach and Achievements
15.6.4 Mergers and Acquisitions
15.7.1 Company Overview
15.7.2 Product Portfolio
15.7.3 Demographic Reach and Achievements
15.7.4 Mergers and Acquisitions
15.8 Pfizer Inc.
15.8.1 Company Overview
15.8.2 Product Portfolio
15.8.3 Demographic Reach and Achievements
15.8.4 Mergers and Acquisitions
15.9 Novartis AG
15.9.1 Company Overview
15.9.2 Product Portfolio
15.9.3 Demographic Reach and Achievements
15.9.4 Mergers and Acquisitions
16 Global Tonic-Clonic Seizures Treatment Market- Drug Distribution Model (Additional Insight)
16.2 Potential Distributors
16.3 Key Parameters for Distribution Partner Assessment
17 Payment Methods (Additional Insight)
17.1 Government Funded
17.2 Private Insurance
*Additional insights provided are customisable as per client requirements.
The market was estimated to reach about a value of USD 3.2 million in 2021.
The market is expected to grow at a CAGR of 6% during the forecast period of 2023-2031.
The market is likely to attain a value of USD 5.4 million by 2030.
The market is segmented based on the product type, drug classification, route of administration, therapeutic channel and region.
The product types are bifurcated into Solid Dosage (Tablets, Capsules) and Liquid Dosage forms (Injectables, Suspension).
The treatment drugs are classified into Barbiturates, Hydantoin, Phenyltriazines, Iminostilbenes, Benzodiazepines, and Aliphatic Carboxylic Acid, among others.
The market growth is expected to be driven by increased incidences of the epilepsy.
The regions involved in this market are North America, Latin America, Asia Pacific, Europe, Middle East and Africa.
Prolonged seizures are clearly capable of causing brain damage. Isolated, brief seizures are likely to result in negative changes in brain function and possibly brain cell loss.
The key companies involved in the market are Johnson & Johnson, GSK plc, Takeda Pharmaceutical, Teva Pharmaceutical Industries, UCB Celltech, Abbott Laboratories, Sanofi, Pfizer Inc., and Novartis AG, among others.
Single User License
Five User License
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.